This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Centre National De La Recherche Scientifique, National Institute of Health and Medical Research, Université Paul Sabatier (Toulouse III). Active years: 2018.
Company Filing History:
1 out of 5,383 
1 out of 1,853 
1 out of 161 
Years Active: 2018
Title: Damien Portevin: Innovator in Anti-Inflammatory Drug Development
Introduction
Damien Portevin is a notable inventor based in London, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-inflammatory drugs. His innovative approach has led to the creation of a unique patent that addresses inflammatory diseases.
Latest Patents
Damien Portevin holds a patent for "Phosphorylated dendrimers as anti-inflammatory drugs." This invention focuses on dendrimers with monophosphonic or bisphosphonic terminations, which are designed for the treatment of inflammatory diseases. His work in this area showcases his commitment to advancing medical science and improving patient outcomes.
Career Highlights
Throughout his career, Damien has worked with esteemed institutions such as Université Paul Sabatier (Toulouse III) and the Centre National de la Recherche Scientifique. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Damien has collaborated with notable colleagues, including Olivier Rolland and Mary Poupot. These partnerships have enriched his research and expanded the impact of his innovations in the pharmaceutical industry.
Conclusion
Damien Portevin's work in developing anti-inflammatory drugs through innovative dendrimer technology highlights his role as a key inventor in the field. His contributions continue to influence medical research and offer hope for effective treatments for inflammatory diseases.